We welcome comments to these policy initiatives.
AATOD’s Five Year Plan (2017 – 2021)
As you will note in reading through the plan, it sets out a broad policy agenda, which will be realized through working in close partnership with many organizations and individuals.We hope you find the topics to be of interest since they also reflect recent surveys that we have conducted among our colleagues throughout the United States, in addition to published policy papers.
- Guidelines for Addressing Benzodiazepine Use in Opioid Treatment Programs (OTPs) (April 6, 2017) The clinical issue of benzodiazepine use and abuse by patients in our treatment programs has been extremely challenging. It is our collective hope that these guidelines will serve as a resource to our membership and the field. The AATOD Board of Directors and I would be interested in receiving your feedback.
- Proposal to Increase Medicaid Utilization for OTPs
- Comments to the Department / SAMHSA recommended changes in the Federal Confidentiality Regulations (April 11, 2016)
- Federal Confidentiality Regulations (June 23, 2014)
- Increasing Access to Medications to Treatment Opioid Addiction – Increasing Access for the Treatment of Opioid Addiction with Medications (July 2, 2014)
- MAT for Opioid Addiction in the Criminal Justice System (April 2014)
Mark Parrino’s (AATOD’s President) letter to the field regarding MAT for Opioid Addiction in the Criminal Justice System has many useful links to the following resources:
- Letter to Attorney General Holder signed by 16 Senators
- LAC’s paper – “Legality of Denying Access to Medication Assisted Treatment in the Criminal Justice System”
- RSAT Training Tool: MAT for Offender Populations
- SAMHSA’s report on the use of Medication-Assisted Treatment and Criminal Justice System
- AATOD’s Response to SAMHSA’s Federal Register Notice of May 16, 2013 in Updating the Accreditation Guidelines for OTPs (July 2013)
- AATOD Guidelines for Using Naltrexone (Vivitrol) in OTPs (March 2013) There are three federally approved medications to treat chronic opioid addiction in the United States: methadone, buprenorphine, and Vivitrol/naltrexone. All three medications can be used as part of treatment for opioid addiction delivered through the federally certified and licensed Opioid Treatment Programs (OTPs). The AATOD Board of Directors believes that it is important for all OTPs to consider using all federally approved medications to treat chronic opioid addiction as we work in greater cooperation with Drug Courts, correctional facilities, and probation and parole offices. It is also important to use all federally approved medications, as noted above, as we prepare for the full implementation of Health Care Reform. READ MORE…
- AATOD Guidelines for Guest Medication (March 2013)
- AATOD’s Five Year Plan
- Challenges and Opportunities (July 2012)
- Washington State Prescription Monitoring Program
Notice to Patient of Evergreen Treatment Services
- Guidance to OTPs Concerning the Use of Prescription Monitoring Program (PMP) Databases
- Medication-Assisted Treatment for Opioid Addiction: Challenges and Solutions – June 2011